Novatarg Pharmaceuticals

Translating Membrane Proteins to Life

 

Novatarg has pioneered an novel approach to accelerate development of molecularly targeted therapies and companion molecular diagnostic devices against membrane proteins. 

 

Novatarg will leverage its unique enabling nanotechnology platform  that is specifically designed to characterize three-dimensional structures of membrane proteins, together with its unparalleled capabilities for membrane protein molecular imaging and screening, to develop more effective targeted drugs faster and at significantly reduced costs.

 

This integrated approach has potential to lead to major advances in developing novel targeted drugs, drug leads and research tools for G protein-coupled receptors (GPCRs),  receptor tyrosine kinases (RTKs) and other membrane proteins involved in disease.  

 

Specifically Novatarg’s advances facilitate design and development of  selective allosteric inhibitors as new pharmacological modalities that overcome resistance associated with conventional active-site inhibitors.  These advances have utility for multiple human disorders, including cancer, diseases of the central nervous system (CNS) and neurodegenerative disorders such as Alzheimer’s Disease, and to overcome multidrug resistance.

To contact us:

© 2010 Novatarg